979 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BIIB Biogen Inc. $334.44 $67.37B Downtrend
Article Searches
BIIB: BMO Capital Markets starts at Market Perform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190222122913 Feb 22, 2019 - BMO Capital Markets issues rating change for BIIB
AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story https://seekingalpha.com/article/4240000-abbvie-suffers-market-loss-humira-europe-u-s-different-story?source=feed_sector_healthcare Feb 11, 2019 - AbbVie missed its Q4 earnings expectations, but it does have many other products to help it get back on track in the coming quarters.The big loss for the quarter was due to international sales of Humi
Top Research Reports for Visa, Charter Communications & Biogen http://www.zacks.com/research-daily/211963/top-research-reports-for-visa-charter-communications-biogen?cid=CS-ZC-FT-211963 Feb 08, 2019 - Top Research Reports for Visa, Charter Communications & Biogen
ClearBridge All Cap Growth Strategy Portfolio Manager Commentary Q4 2018 https://seekingalpha.com/article/4237809-clearbridge-cap-growth-strategy-portfolio-manager-commentary-q4-2018?source=feed_all_articles Feb 04, 2019 -
Ionis Wins Price Target Hike On Partner Biogen's Guidance http://feeds.benzinga.com/~r/benzinga/~3/F25es8s5L7w/ionis-wins-price-target-hike-on-partner-biogens-guidanc Jan 30, 2019 -

Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s partner Biogen Inc (NASDAQ: BIIB) reported

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4236353-biogen-inc-biib-ceo-michel-vounatsos-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Jan 29, 2019 -
Biogen Inc (BIIB) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/01/29/biogen-inc-biib-q4-2018-earnings-conference-call-t.aspx?source=iedfolrf0000001 Jan 29, 2019 - BIIB earnings call for the period ending December 31, 2018.
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/350499/biogen-biib-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-350499 Jan 29, 2019 - Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
Biogen Inc. 2018 Q4 - Results - Earnings Call Slides https://seekingalpha.com/article/4236192-biogen-inc-2018-q4-results-earnings-call-slides?source=feed_sector_healthcare Jan 29, 2019 - The following slide deck was published by Biogen Inc. in conjunction with their 2018 Q4 earnings call.
Biotech Bio Series #5: Stay Clear Of Biogen https://seekingalpha.com/article/4236113-biotech-bio-series-5-stay-clear-biogen?source=feed_sector_healthcare Jan 28, 2019 - Biogen’s largest revenue driver, its multiple sclerosis franchise, has seen stagnant growth and has a bleak future ahead.Its new drug Spinraza is growing strong but faces severe impending competition

Pages: 123456...98

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $72.78 $94.35B
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
QGEN Qiagen N.V. NYSE $37.42 $8.5B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Biogen
BIIB - Google Finance https://www.google.com/finance?q=BIIB Industry related info and international coverage Summary News
BIIB - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=BIIB Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options